Semaglutide consistently reduces both fasting and postprandial glucose levels across SUSTAIN 1-5 clinical trials

Semaglutide, a GLP-1 analog in development for once-weekly treatment of T2D has demonstrated superior reductions in HbA1c across SUSTAIN 1–5 clinical trials vs comparators. Improvements in fasting and postprandial plasma glucose (FPG; PPG) levels are major contributors to achieving HbA1c targets in subjects with T2D. The effect of once-weekly semaglutide vs comparators (placebo, sitagliptin, exenatide ER, insulin glargine [IGlar], placebo with basal insulin) on FPG and PPG was investigated.